Literature DB >> 12684916

Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000.

Mamta K Jain1, Daniel J Skiest, Jeff W Cloud, Charu L Jain, Dennis Burns, Ruth E Berggren.   

Abstract

We conducted a retrospective chart review of human immunodeficiency virus (HIV)-infected patients who died in 1995 and in 1999-2000. We found an increase in the proportion of patients who died from an illness that was not related to acquired immunodeficiency syndrome (AIDS). Although there was a decrease in the prevalence of AIDS-defining illnesses, >85% of patients died with CD4 counts of <200 cells/microL. The leading cause of death was Pneumocystis carinii pneumonia (PCP). Nonadherence to therapy and new diagnosis of HIV infection were the leading reasons why patients were not receiving antiretroviral therapy. The leading causes of non-AIDS-related deaths in 1999-2000 were non-AIDS-defining infections and end-stage liver disease. At our hospital, PCP remains an important cause of death in the highly active antiretroviral therapy (HAART) era, possibly because >50% of HIV-infected patients who died were not receiving HAART. AIDS-defining illnesses continue to be a major cause of mortality in the HAART era in populations where access to care and adherence to HAART is limited.

Entities:  

Mesh:

Year:  2003        PMID: 12684916     DOI: 10.1086/368186

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

Review 1.  The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?

Authors:  Thomas P Giordano; Maria E Suarez-Almazor; Richard M Grimes
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 2.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

3.  Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era.

Authors:  Isaline Coquet; Juliette Pavie; Pierre Palmer; François Barbier; Stéphane Legriel; Julien Mayaux; Jean Michel Molina; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2010-06-09       Impact factor: 9.097

4.  Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

Authors:  Tess Petersen; Yu-Jin Lee; Anu Osinusi; Valerianna K Amorosa; Crystal Wang; Minhee Kang; Roy Matining; Xiao Zhang; Diana Dou; Triin Umbleja; Shyam Kottilil; Marion G Peters
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-14       Impact factor: 2.205

5.  Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Authors:  Lindsay Matthews; David E Kleiner; Cheryl Chairez; Maryellen McManus; Mary Jane Nettles; Kira Zemanick; Caryn Gee Morse; Debra Benator; Joseph A Kovacs; Colleen Hadigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

6.  Changes in the socio-demographics, risk behaviors, clinical and immunological profile of a cohort of the Puerto Rican population living with HIV: an update of the Retrovirus Research Center (1992-2008).

Authors:  Christine Miranda; Diana M Fernandez; Raul O Ramon; Miriam Velázquez; Angel M Mayor; Robert F Hunter-Mellado
Journal:  Bol Asoc Med P R       Date:  2010 Jul-Sep

7.  Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Authors:  Diana C Lemly; Bryan E Shepherd; Todd Hulgan; Peter Rebeiro; Samuel Stinnette; Robert B Blackwell; Sally Bebawy; Asghar Kheshti; Timothy R Sterling; Stephen P Raffanti
Journal:  J Infect Dis       Date:  2009-04-01       Impact factor: 5.226

8.  Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.

Authors:  Lynn Rozenberg; Bart L Haagmans; Avidan U Neumann; Grace Chen; Mary McLaughlin; Rachel S Levy-Drummer; H Masur; Robin L Dewar; Peter Ferenci; Marcelo Silva; Maria S Viola; Michael A Polis; Shyam Kottilil
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

9.  Determination of the underlying cause of death in three multicenter international HIV clinical trials.

Authors:  Alan R Lifson; Waldo H Belloso; Cate Carey; Richard T Davey; Daniel Duprez; Wafaa M El-Sadr; Jose M Gatell; Daniela C Gey; Jennifer F Hoy; Eric A Krum; Ray Nelson; Daniel E Nixon; Nick Paton; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James Sampson; John Worley
Journal:  HIV Clin Trials       Date:  2008 May-Jun

10.  AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.

Authors:  Angel M Mayor; María A Gómez; Eddy Ríos-Olivares; Robert F Hunter-Mellado
Journal:  Ethn Dis       Date:  2008       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.